Published on December 5, 2009 at 1:43 AM
Emerging Healthcare Solutions, Inc. (PinkSheets: EHSI) today announced the Company has entered into discussions with a Houston-based medical company relating to its patented, and patent pending, genetics technologies. Emerging Healthcare expects the negotiations will result in the companies agreeing to work together to deliver these cutting edge stem cell technologies to national and international medical markets.
The National Institutes of Health recently announced that at least 33 additional embryonic stem cell lines will be added to a national registry. This more than doubles the available stem cell lines that researchers have been able to utilize since a Bush administration moratorium on stem cell lines created after August 9, 2001. The Obama administration recently overturned the moratorium leading to at least 96 additional lines being under review by NIH.
Other publically-held companies involved in stem cell research include Geron Corp. (NASDAQ: GERN), Pfizer, Inc. (NYSE: PFE), and Stem Cells, Inc. (NASDAQ: STEM). The increased access to stem cell lines, concurrent with additional federal research funding should accelerate the delivery of stem cell derived therapies.
Source: Emerging Healthcare Solutions, Inc.